{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T18:40:25Z","timestamp":1766428825358,"version":"3.44.0"},"reference-count":158,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.neuropharm.2022.108959","type":"journal-article","created":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T01:44:07Z","timestamp":1642383847000},"page":"108959","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["New approaches to treatments for sleep, pain and autonomic failure in Parkinson's disease - Pharmacological therapies"],"prefix":"10.1016","volume":"208","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8744-5058","authenticated-orcid":false,"given":"Katarina","family":"Rukavina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Batzu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Leta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2815-0505","authenticated-orcid":false,"given":"K Ray","family":"Chaudhuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.neuropharm.2022.108959_bib3","first-page":"1999","article-title":"Treatment of neuropathic pain with venlafaxine: a systematic review","volume":"18","author":"Aiyer","year":"2017","journal-title":"Pain Med."},{"issue":"6","key":"10.1016\/j.neuropharm.2022.108959_bib4","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/mds.870120617","article-title":"Constipation in Parkinson's disease: objective assessment and response to psyllium","volume":"12","author":"Ashraf","year":"1997","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"10.1016\/j.neuropharm.2022.108959_bib5","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1146\/annurev-pharmtox-010818-021524","article-title":"Neuropathic pain: mechanism-based therapeutics","volume":"60","author":"Bannister","year":"2020","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"1","key":"10.1016\/j.neuropharm.2022.108959_bib6","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41531-021-00173-y","article-title":"Towards optimising experimental quantification of persistent pain in Parkinson's disease using psychophysical testing","volume":"7","author":"Bannister","year":"2021","journal-title":"NPJ Parkinson's disease"},{"issue":"11","key":"10.1016\/j.neuropharm.2022.108959_bib7","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1002\/mds.22643","article-title":"The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease","volume":"24","author":"Barone","year":"2009","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2022.108959_bib8","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1161\/HYPERTENSIONAHA.114.04035","article-title":"Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa","volume":"65","author":"Biaggioni","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.neuropharm.2022.108959_bib9","doi-asserted-by":"crossref","first-page":"146521","DOI":"10.1016\/j.brainres.2019.146521","article-title":"Antinociceptive effects of treadmill exercise in a rat model of Parkinson's disease: the role of cannabinoid and opioid receptors","volume":"1727","author":"Binda","year":"2020","journal-title":"Brain Res."},{"issue":"4","key":"10.1016\/j.neuropharm.2022.108959_bib10","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1389-9457(03)00072-8","article-title":"Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients","volume":"4","author":"Boeve","year":"2003","journal-title":"Sleep Med."},{"issue":"1","key":"10.1016\/j.neuropharm.2022.108959_bib11","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1017\/cjn.2017.245","article-title":"Botulinum toxin type A for pain in advanced Parkinson's disease","volume":"45","author":"Bruno","year":"2018","journal-title":"Can. J. Neurol. Sci."},{"issue":"4","key":"10.1016\/j.neuropharm.2022.108959_bib12","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1007\/s00415-017-8426-y","article-title":"Pain in Parkinson disease: a cross-sectional survey of its prevalence, specifics, and therapy","volume":"264","author":"Buhmann","year":"2017","journal-title":"J. Neurol."},{"issue":"9","key":"10.1016\/j.neuropharm.2022.108959_bib13","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s40263-019-00661-z","article-title":"Apomorphine for Parkinson's disease: efficacy and safety of current and new formulations","volume":"33","author":"Carbone","year":"2019","journal-title":"CNS Drugs"},{"issue":"7","key":"10.1016\/j.neuropharm.2022.108959_bib14","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1212\/01.WNL.0000140288.48796.8E","article-title":"Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study","volume":"63","author":"Carroll","year":"2004","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.neuropharm.2022.108959_bib15","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3233\/JPD-160911","article-title":"Effects of safinamide on pain in fluctuating Parkinson's disease patients: a post-hoc analysis","volume":"7","author":"Cattaneo","year":"2017","journal-title":"J. Parkinsons Dis."},{"issue":"4","key":"10.1016\/j.neuropharm.2022.108959_bib16","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s12325-018-0687-z","article-title":"Long-term efficacy of safinamide on Parkinson's disease chronic pain","volume":"35","author":"Cattaneo","year":"2018","journal-title":"Adv. Ther."},{"issue":"1","key":"10.1016\/j.neuropharm.2022.108959_bib17","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10286-021-00771-z","article-title":"Thirty years of research on autonomic dysfunction, non-motor features, and endophenotypes in Parkinson disease","volume":"31","author":"Chaudhuri","year":"2021","journal-title":"Clin. Auton. Res. Off. J. Clin. Aut. Res. Soc."},{"issue":"5","key":"10.1016\/j.neuropharm.2022.108959_bib18","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1474-4422(09)70068-7","article-title":"Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment","volume":"8","author":"Chaudhuri","year":"2009","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2022.108959_bib19","doi-asserted-by":"crossref","first-page":"28","DOI":"10.17925\/ENR.2019.14.1.28","article-title":"Societal burden and persisting unmet needs of Parkinson's disease","volume":"14","author":"Chaudhuri","year":"2019","journal-title":"Eur. Neurol. Rev."},{"issue":"12","key":"10.1016\/j.neuropharm.2022.108959_bib20","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/mds.26270","article-title":"King's Parkinson's disease pain scale, the first scale for pain in PD: an international validation","volume":"30","author":"Chaudhuri","year":"2015","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"issue":"10","key":"10.1016\/j.neuropharm.2022.108959_bib21","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1038\/ajg.2011.162","article-title":"A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation","volume":"106","author":"Chey","year":"2011","journal-title":"Am. J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.neuropharm.2022.108959_bib22","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/nau.24552","article-title":"Mirabegron for treatment of overactive bladder symptoms in patients with Parkinson's disease: a double-blind, randomized placebo-controlled trial (Parkinson's Disease Overactive bladder Mirabegron, PaDoMi Study)","volume":"40","author":"Cho","year":"2021","journal-title":"Neurourol. Urodyn."},{"key":"10.1016\/j.neuropharm.2022.108959_bib23","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41531-019-0081-9","article-title":"Contractile dysfunction and nitrergic dysregulation in small intestine of a primate model of Parkinson's disease","volume":"5","author":"Coletto","year":"2019","journal-title":"NPJ Parkinson's disease"},{"issue":"8","key":"10.1016\/j.neuropharm.2022.108959_bib24","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1212\/01.WNL.0000158652.74601.48","article-title":"Nocturnal activity with nighttime pergolide in Parkinson disease: a controlled study using actigraphy","volume":"64","author":"Comella","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2022.108959_bib25","article-title":"Rascol O THN 102, an association of modafinil and low dose flecainide, in the treatment of excessive daytime sleepiness associated with Parkinson disease: a double-blind, placebo controlled study","author":"Corvol","year":"2020","journal-title":"MDS Virtual Congress"},{"issue":"1","key":"10.1016\/j.neuropharm.2022.108959_bib26","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/mds.23406","article-title":"Apomorphine effect on pain threshold in Parkinson's disease: a clinical and positron emission tomography study","volume":"26","author":"Dellapina","year":"2011","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"issue":"4","key":"10.1016\/j.neuropharm.2022.108959_bib27","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/wnf.0b013e3180340319","article-title":"The effect of duloxetine on primary pain symptoms in Parkinson disease","volume":"30","author":"Djaldetti","year":"2007","journal-title":"Clin. Neuropharmacol."},{"issue":"5","key":"10.1016\/j.neuropharm.2022.108959_bib28","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.sleep.2005.04.004","article-title":"Melatonin for sleep disturbances in Parkinson's disease","volume":"6","author":"Dowling","year":"2005","journal-title":"Sleep Med."},{"key":"10.1016\/j.neuropharm.2022.108959_bib29","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.sleep.2017.03.028","article-title":"Safety and efficacy of long-term use of sodium oxybate for narcolepsy with cataplexy in routine clinical practice","volume":"35","author":"Drakatos","year":"2017","journal-title":"Sleep Med."},{"issue":"4","key":"10.1016\/j.neuropharm.2022.108959_bib30","doi-asserted-by":"crossref","DOI":"10.1097\/WNF.0000000000000041","article-title":"Influence of the nonergot dopamine agonist piribedil on vigilance in patients with Parkinson disease and excessive daytime sleepiness (PiViCog-PD): an 11-week randomized comparison trial against pramipexole and ropinirole","volume":"37","author":"Eggert","year":"2014","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2022.108959_bib31","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.parkreldis.2021.02.016","article-title":"Excessive daytime sleepiness in Parkinson\u2019s disease: a systematic review and meta-analysis","volume":"85","author":"Feng","year":"2021","journal-title":"Park. Relat. Disord."},{"issue":"4","key":"10.1016\/j.neuropharm.2022.108959_bib32","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1097\/01.ju.0000055520.88377.dc","article-title":"Effects of subthalamic nucleus stimulation on urodynamic findings in patients with Parkinson's disease","volume":"169","author":"Finazzi-Agr\u00f2","year":"2003","journal-title":"J. Urol."},{"issue":"2","key":"10.1016\/j.neuropharm.2022.108959_bib33","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10286-011-0119-5","article-title":"Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome","volume":"21","author":"Freeman","year":"2011","journal-title":"Clin. Auton. Res. Off. J. Clin. Aut. Res. Soc."},{"issue":"2","key":"10.1016\/j.neuropharm.2022.108959_bib34","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/mdc3.12577","article-title":"Linaclotide and prucalopride for management of constipation in patients with parkinsonism","volume":"5","author":"Freitas","year":"2018","journal-title":"Mov. Disord. Clin. Pract."},{"key":"10.1016\/j.neuropharm.2022.108959_bib35","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.2147\/JPR.S164939","article-title":"Effects of tapentadol on pain, motor symptoms and cognitive functions in Parkinson's disease","volume":"11","author":"Freo","year":"2018","journal-title":"J. Pain Res."},{"issue":"13","key":"10.1016\/j.neuropharm.2022.108959_bib36","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1111\/bph.13215","article-title":"Cannabinoid-dopamine interactions in the physiology and physiopathology of the basal ganglia","volume":"173","author":"Garcia","year":"2016","journal-title":"Br. J. Pharmacol."},{"issue":"8","key":"10.1016\/j.neuropharm.2022.108959_bib37","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s00702-020-02218-7","article-title":"Effects of safinamide on pain in Parkinson's disease with motor fluctuations: an exploratory study","volume":"127","author":"Geroin","year":"2020","journal-title":"J. Neural. Transm."},{"issue":"4","key":"10.1016\/j.neuropharm.2022.108959_bib38","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.3233\/JPD-202088","article-title":"A dual Centre study of pain in Parkinson's disease and its relationship with other non-motor symptoms","volume":"10","author":"Ghosh","year":"2020","journal-title":"J. Parkinsons Dis."},{"issue":"3","key":"10.1016\/j.neuropharm.2022.108959_bib39","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.juro.2011.04.071","article-title":"Botulinum toxin type A in patients with Parkinson's disease and refractory overactive bladder","volume":"186","author":"Giannantoni","year":"2011","journal-title":"J. Urol."},{"issue":"2","key":"10.1016\/j.neuropharm.2022.108959_bib40","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/mds.27886","article-title":"Melatonin for rapid eye movement sleep behavior disorder in Parkinson's disease: a randomised controlled trial","volume":"35","author":"Gilat","year":"2020","journal-title":"Mov. Disord."},{"issue":"9","key":"10.1016\/j.neuropharm.2022.108959_bib41","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/j.1532-2149.2012.00134.x","article-title":"Contribution of genetic variants to pain susceptibility in Parkinson disease","volume":"16","author":"Greenbaum","year":"2012","journal-title":"Eur. J. Pain"},{"issue":"10","key":"10.1016\/j.neuropharm.2022.108959_bib42","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.2336","article-title":"Effects of safinamide on pain in patients with fluctuating Parkinson\u2019s disease","volume":"11","author":"Grigoriou","year":"2021","journal-title":"Brain Behav"},{"issue":"1","key":"10.1016\/j.neuropharm.2022.108959_bib43","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3233\/JPD-130259","article-title":"Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson's disease (NOH306A)","volume":"4","author":"Hauser","year":"2014","journal-title":"J. Parkinsons Dis."},{"issue":"5","key":"10.1016\/j.neuropharm.2022.108959_bib44","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/mds.26086","article-title":"Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson's disease (nOH306B)","volume":"30","author":"Hauser","year":"2015","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"issue":"9","key":"10.1016\/j.neuropharm.2022.108959_bib45","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/ejp.1297","article-title":"European Pain Federation (EFIC) position paper on appropriate use of cannabis-based medicines and medical cannabis for chronic pain management","volume":"22","author":"Hauser","year":"2018","journal-title":"Eur. J. Pain"},{"key":"10.1016\/j.neuropharm.2022.108959_bib46","first-page":"2","article-title":"Targeting neurons in the gastrointestinal tract to treat Parkinson's disease","volume":"1","author":"Hauser","year":"2019","journal-title":"Clin. Park. Relat. Disord."},{"issue":"3","key":"10.1016\/j.neuropharm.2022.108959_bib47","doi-asserted-by":"crossref","DOI":"10.1097\/PRS.0000000000006559","article-title":"The use of Botulinum toxin in pain management: basic science and clinical applications","volume":"145","author":"Hehr","year":"2020","journal-title":"Plast. Reconstr. Surg."},{"issue":"8","key":"10.1016\/j.neuropharm.2022.108959_bib48","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/sleep\/25.8.62","article-title":"Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial","volume":"25","author":"H\u00f6gl","year":"2002","journal-title":"Sleep"},{"issue":"Suppl 1","key":"10.1016\/j.neuropharm.2022.108959_bib49","article-title":"International Association for the Study of Pain Presidential Task Force on Cannabis and Cannabinoid Analgesia position statement","volume":"162","year":"2021","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2022.108959_bib50","doi-asserted-by":"crossref","first-page":"116833","DOI":"10.1016\/j.jns.2020.116833","article-title":"A double-blind, randomized controlled trial of duloxetine for pain in Parkinson's disease","volume":"414","author":"Iwaki","year":"2020","journal-title":"J. Neurol. Sci."},{"issue":"1","key":"10.1016\/j.neuropharm.2022.108959_bib51","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/0002-9343(93)90230-M","article-title":"Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine","volume":"95","author":"Jankovic","year":"1993","journal-title":"Am. J. Med."},{"issue":"1","key":"10.1016\/j.neuropharm.2022.108959_bib52","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s12640-019-00109-8","article-title":"Cannabidiol and cannabinoid compounds as potential strategies for treating Parkinson's disease and L-DOPA-induced dyskinesia","volume":"37","author":"Junior","year":"2020","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.neuropharm.2022.108959_bib53","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.urology.2015.09.026","article-title":"The clinical and urodynamic results of percutaneous posterior tibial nerve stimulation on neurogenic detrusor overactivity in patients with Parkinson's disease","volume":"87","author":"Kabay","year":"2016","journal-title":"Urology"},{"issue":"12","key":"10.1016\/j.neuropharm.2022.108959_bib54","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1111\/nmo.12459","article-title":"New ghrelin agonist, HM01 alleviates constipation and L-dopa-delayed gastric emptying in 6-hydroxydopamine rat model of Parkinson's disease","volume":"26","author":"Karasawa","year":"2014","journal-title":"Neurogastroenterol. Motil. Off. J. Eur. Gastrointest. Motil. Soc."},{"key":"10.1016\/j.neuropharm.2022.108959_bib55","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1471-2377-14-42","article-title":"Rotigotine transdermal system and evaluation of pain in patients with Parkinson's disease: a post hoc analysis of the RECOVER study","volume":"14","author":"Kassubek","year":"2014","journal-title":"BMC Neurol."},{"issue":"4","key":"10.1016\/j.neuropharm.2022.108959_bib56","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1212\/WNL.0000000000000615","article-title":"Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial","volume":"83","author":"Kaufmann","year":"2014","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.neuropharm.2022.108959_bib57","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/s00415-019-09651-z","article-title":"New awakenings: current understanding of sleep dysfunction and its treatment in Parkinson's disease","volume":"267","author":"Keir","year":"2020","journal-title":"J. Neurol."},{"key":"10.1016\/j.neuropharm.2022.108959_bib58","doi-asserted-by":"crossref","DOI":"10.5620\/eht.2012.27.e2012007","article-title":"Practical use and risk of modafinil, a novel waking drug","volume":"27","author":"Kim","year":"2012","journal-title":"Environ. Health Toxicol."},{"issue":"5","key":"10.1016\/j.neuropharm.2022.108959_bib59","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1016\/j.juro.2011.12.062","article-title":"Suppression of bladder overactivity by adenosine A2A receptor antagonist in a rat model of Parkinson disease","volume":"187","author":"Kitta","year":"2012","journal-title":"J. Urol."},{"issue":"5","key":"10.1016\/j.neuropharm.2022.108959_bib60","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/j.juro.2015.11.039","article-title":"Role of the anterior cingulate cortex in the control of micturition reflex in a rat model of Parkinson's disease","volume":"195","author":"Kitta","year":"2016","journal-title":"J. Urol."},{"issue":"10","key":"10.1016\/j.neuropharm.2022.108959_bib61","first-page":"893","article-title":"Clinical efficacy of istradefylline on lower urinary tract symptoms in Parkinson's disease","volume":"23","author":"Kitta","year":"2016","journal-title":"Int. J. Urol. Off. J. Jpn. Urol. Assoc."},{"issue":"3","key":"10.1016\/j.neuropharm.2022.108959_bib62","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/WNF.0000000000000281","article-title":"Long-term outcome of adenosine A2A receptor antagonist on lower urinary tract symptoms in male Parkinson disease patients","volume":"41","author":"Kitta","year":"2018","journal-title":"Clin. Neuropharmacol."},{"issue":"10","key":"10.1016\/j.neuropharm.2022.108959_bib63","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1002\/mds.28186","article-title":"High glucosylceramides and low anandamide contribute to sensory loss and pain in Parkinson's disease","volume":"35","author":"Klatt-Schreiner","year":"2020","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"issue":"1","key":"10.1016\/j.neuropharm.2022.108959_bib64","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/mds.26866","article-title":"Constipation in Parkinson's disease: subjective symptoms, objective markers, and new perspectives","volume":"32","author":"Knudsen","year":"2017","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"issue":"5","key":"10.1016\/j.neuropharm.2022.108959_bib65","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1176\/appi.psy.46.5.379","article-title":"Evaluation of reboxetine, a noradrenergic antidepressant, for the treatment of fibromyalgia and chronic low back pain","volume":"46","author":"Krell","year":"2005","journal-title":"Psychosomatics"},{"issue":"2","key":"10.1016\/j.neuropharm.2022.108959_bib66","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/bph.12324","article-title":"Orexin\/hypocretin receptor signalling cascades","volume":"171","author":"Kukkonen","year":"2014","journal-title":"Br. J. Pharmacol."},{"issue":"8","key":"10.1016\/j.neuropharm.2022.108959_bib67","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.parkreldis.2010.06.006","article-title":"Use of botulinim toxin-A for the treatment of overactive bladder symptoms in patients with Parkinsons's disease","volume":"16","author":"Kulaksizoglu","year":"2010","journal-title":"Park. Relat. Disord."},{"issue":"7","key":"10.1016\/j.neuropharm.2022.108959_bib68","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/nau.22645","article-title":"Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a \u03b23-adrenoceptor agonist, in patients with overactive bladder in Asia","volume":"34","author":"Kuo","year":"2015","journal-title":"Neurourol. Urodyn."},{"issue":"4","key":"10.1016\/j.neuropharm.2022.108959_bib69","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1097\/j.pain.0000000000002111","article-title":"Pain in the neurodegenerating brain: insights into pharmacotherapy for Alzheimer disease and Parkinson disease","volume":"162","author":"Lawn","year":"2020","journal-title":"Pain"},{"issue":"8","key":"10.1016\/j.neuropharm.2022.108959_bib158","doi-asserted-by":"crossref","first-page":"773","DOI":"10.3390\/jpm11080773","article-title":"Personalised advanced therapies in Parkinson\u2019s disease: the role of non-motor symptoms pofile","volume":"11","author":"Leta","year":"2021","journal-title":"J. Pers. Med."},{"issue":"12","key":"10.1016\/j.neuropharm.2022.108959_bib70","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1080\/14740338.2019.1681966","article-title":"Can therapeutic strategies prevent and manage dyskinesia in Parkinson's disease? An update","volume":"18","author":"Leta","year":"2019","journal-title":"Expet Opin. Drug Saf."},{"key":"10.1016\/j.neuropharm.2022.108959_bib71","first-page":"19","article-title":"Chapter Two - general approach to patients with autonomic dysfunction in Parkinson's disease","volume":"vol. 1","author":"Leta","year":"2021"},{"key":"10.1016\/j.neuropharm.2022.108959_bib72","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.bbi.2021.07.026","article-title":"Neurogenic and anti-inflammatory effects of probiotics in Parkinson's disease: a systematic review of preclinical and clinical evidence","volume":"98","author":"Leta","year":"2021","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.neuropharm.2022.108959_bib73","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.parkreldis.2020.09.024","article-title":"Unmet needs in Parkinson disease: motor and non-motor","volume":"80","author":"LeWitt","year":"2020","journal-title":"Park. Relat. Disord."},{"issue":"3","key":"10.1016\/j.neuropharm.2022.108959_bib74","doi-asserted-by":"crossref","first-page":"275","DOI":"10.4196\/kjpp.2015.19.3.275","article-title":"Effect of glutamate on the vestibulo-solitary projection after sodium nitroprusside-induced hypotension in conscious rats","volume":"19","author":"Li","year":"2015","journal-title":"Korean J. Physiol. Pharmacol. Off. J. Kor. Physiol. Soc. Kor. Soc. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.108959_bib75","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.neulet.2018.07.027","article-title":"Association of Parkinson's disease-related pain with plasma interleukin-1, interleukin-6, interleukin-10, and tumour necrosis factor-alpha","volume":"683","author":"Li","year":"2018","journal-title":"Neurosci. Lett."},{"issue":"4","key":"10.1016\/j.neuropharm.2022.108959_bib76","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.bbrc.2019.10.204","article-title":"Sensation of TRPV1 via 5-hydroxytryptamine signaling modulates pain hypersensitivity in a 6-hydroxydopamine induced mice model of Parkinson's disease","volume":"521","author":"Li","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neuropharm.2022.108959_bib77","doi-asserted-by":"crossref","first-page":"173693","DOI":"10.1016\/j.ejphar.2020.173693","article-title":"Antinociceptive effects of rotigotine-loaded microspheres and its synergistic interactions with analgesics in inflammatory pain in rats","volume":"891","author":"Li","year":"2021","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2022.108959_bib78","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1001\/jamaneurol.2015.2904","article-title":"A case of rapid eye movement sleep behavior disorder in Parkinson disease treated with sodium oxybate","volume":"73","author":"Liebenthal","year":"2016","journal-title":"JAMA Neurol."},{"issue":"6","key":"10.1016\/j.neuropharm.2022.108959_bib1","doi-asserted-by":"crossref","DOI":"10.1002\/mds.20387","article-title":"Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients","volume":"20","author":"Liu","year":"2005","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2022.108959_bib79","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3389\/fneur.2017.00042","article-title":"The treatment of sleep disorders in Parkinson's disease: from research to clinical practice","volume":"8","author":"Loddo","year":"2017","journal-title":"Front. Neurol."},{"issue":"2","key":"10.1016\/j.neuropharm.2022.108959_bib80","first-page":"37","article-title":"Comparative assessment of combined therapy of neurogenic hyperactivity of detrusor in patients with Parkinson's disease","author":"Loran","year":"2006","journal-title":"Urologiia"},{"issue":"13","key":"10.1016\/j.neuropharm.2022.108959_bib81","first-page":"1046","article-title":"Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study","volume":"277","author":"Low","year":"1997","journal-title":"Midodrine Study Group. JAMA"},{"issue":"8","key":"10.1016\/j.neuropharm.2022.108959_bib82","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s00192-011-1641-7","article-title":"Solifenacin for overactive bladder: a systematic review and meta-analysis","volume":"23","author":"Luo","year":"2012","journal-title":"Int. Urogynecol. J."},{"issue":"1","key":"10.1016\/j.neuropharm.2022.108959_bib83","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00540-019-02680-y","article-title":"Medical cannabis for chronic pain: can it make a difference in pain management?","volume":"34","author":"Maharajan","year":"2020","journal-title":"J. Anesth."},{"issue":"2","key":"10.1016\/j.neuropharm.2022.108959_bib84","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1515\/sjpain-2020-0151","article-title":"Although tapentadol and oxycodone both increase colonic volume, tapentadol treatment resulted in softer stools and less constipation: a mechanistic study in healthy volunteers","volume":"21","author":"Mark","year":"2021","journal-title":"Scand J Pain"},{"issue":"3","key":"10.1016\/j.neuropharm.2022.108959_bib85","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/mds.23462","article-title":"The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease","volume":"26","author":"Martinez-Martin","year":"2011","journal-title":"Mov. Disord."},{"issue":"3","key":"10.1016\/j.neuropharm.2022.108959_bib86","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.sleep.2012.09.018","article-title":"Treatment outcomes in REM sleep behavior disorder","volume":"14","author":"McCarter","year":"2013","journal-title":"Sleep Med."},{"key":"10.1016\/j.neuropharm.2022.108959_bib87","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.parkreldis.2016.10.024","article-title":"Lower urinary tract symptoms in Parkinson's disease: prevalence, aetiology and management","volume":"35","author":"McDonald","year":"2017","journal-title":"Park. Relat. Disord."},{"issue":"5","key":"10.1016\/j.neuropharm.2022.108959_bib88","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/mds.27003","article-title":"Degeneration of rapid eye movement sleep circuitry underlies rapid eye movement sleep behavior disorder","volume":"32","author":"McKenna","year":"2017","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/j.neuropharm.2022.108959_bib89","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00415-006-0390-x","article-title":"Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson's disease","volume":"254","author":"Medeiros","year":"2007","journal-title":"J. Neurol."},{"issue":"7","key":"10.1016\/j.neuropharm.2022.108959_bib90","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/mds.20412","article-title":"Driving in Parkinson's disease: mobility, accidents, and sudden onset of sleep at the wheel","volume":"20","author":"Meindorfner","year":"2005","journal-title":"Mov. Disord."},{"issue":"11","key":"10.1016\/j.neuropharm.2022.108959_bib91","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1002\/mds.23168","article-title":"Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo","volume":"25","author":"Menza","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2022.108959_bib92","article-title":"Gastrointestinal dysfunction in Parkinson\u2019s disease: molecular pathology and implications of gut microbiome, probiotics, and fecal microbiota transplantation","author":"Metta","year":"2021","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.neuropharm.2022.108959_bib93","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3233\/JPD-140509","article-title":"Local change in urinary bladder contractility following CNS dopamine denervation in the 6-OHDA rat model of Parkinson's disease","volume":"5","author":"Mitra","year":"2015","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.neuropharm.2022.108959_bib94","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.sleep.2016.04.014","article-title":"Sodium oxybate for idiopathic REM sleep behavior disorder: a report on two patients","volume":"32","author":"Moghadam","year":"2017","journal-title":"Sleep Med."},{"issue":"7","key":"10.1016\/j.neuropharm.2022.108959_bib95","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/mds.10473","article-title":"The unified Parkinson's disease rating scale (UPDRS): status and recommendations","volume":"18","year":"2003","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"issue":"6","key":"10.1016\/j.neuropharm.2022.108959_bib96","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1080\/14656566.2020.1726319","article-title":"The pharmacological management of constipation in patients with Parkinson's disease: a much-needed relief","volume":"21","author":"Mozaffari","year":"2020","journal-title":"Expet Opin. Pharmacother."},{"issue":"8","key":"10.1016\/j.neuropharm.2022.108959_bib97","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S2468-1253(18)30123-7","article-title":"Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial","volume":"3","author":"Nakajima","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.neuropharm.2022.108959_bib98","first-page":"459","article-title":"Cannabinoid CB1 and CB2 receptors, and monoacylglycerol lipase gene expression alterations in the basal ganglia of patients with Parkinson's disease","volume":"15","author":"Navarrete","year":"2018","journal-title":"Neurother. J. Am. Soc. Exp. Neurother."},{"key":"10.1016\/j.neuropharm.2022.108959_bib99","series-title":"Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie","first-page":"936","article-title":"Transcutaneous tibial nerve stimulation in the overactive bladder syndrome in patients with Parkinson's syndromes","volume":"23","author":"Ohannessian","year":"2013"},{"issue":"3","key":"10.1016\/j.neuropharm.2022.108959_bib100","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1161\/HYPERTENSIONAHA.111.184812","article-title":"Synergistic effect of norepinephrine transporter blockade and \u03b1-2 antagonism on blood pressure in autonomic failure","volume":"59","author":"Okamoto","year":"2012","journal-title":"Hypertension"},{"issue":"12","key":"10.1016\/j.neuropharm.2022.108959_bib101","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1136\/jnnp.2005.065870","article-title":"Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial","volume":"76","author":"Ondo","year":"2005","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"21","key":"10.1016\/j.neuropharm.2022.108959_bib102","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1212\/WNL.0b013e3182574f28","article-title":"Placebo-controlled trial of lubiprostone for constipation associated with Parkinson disease","volume":"78","author":"Ondo","year":"2012","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.neuropharm.2022.108959_bib103","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.cger.2019.09.002","article-title":"Orthostatic hypotension in Parkinson disease","volume":"36","author":"Palma","year":"2020","journal-title":"Clin. Geriatr. Med."},{"issue":"6","key":"10.1016\/j.neuropharm.2022.108959_bib104","doi-asserted-by":"crossref","first-page":"675","DOI":"10.4196\/kjpp.2017.21.6.675","article-title":"Dual control of the vestibulosympathetic reflex following hypotension in rats","volume":"21","author":"Park","year":"2017","journal-title":"Korean J. Physiol. Pharmacol. Off. J. Kor. Physiol. Soc. Kor. Soc. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.108959_bib2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.parkreldis.2017.02.003","article-title":"A randomized trial of relamorelin for constipation in Parkinson\u2019s disease (MOVE-PD): trial results and lessons learned","volume":"37","year":"2017","journal-title":"Park. Relat. Disord."},{"issue":"6","key":"10.1016\/j.neuropharm.2022.108959_bib105","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/mds.10417","article-title":"Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease","volume":"18","author":"Paus","year":"2003","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2022.108959_bib106","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.parkreldis.2018.07.005","article-title":"Mirabegron in patients with Parkinson disease and overactive bladder symptoms: a retrospective cohort","volume":"57","author":"Peyronnet","year":"2018","journal-title":"Park. Relat. Disord."},{"issue":"4","key":"10.1016\/j.neuropharm.2022.108959_bib107","first-page":"1464","article-title":"Autonomic dysfunction in Parkinson's disease","volume":"17","author":"Pfeiffer","year":"2020","journal-title":"Neurother. J. Am. Soc. Exp. Neurother."},{"key":"10.1016\/j.neuropharm.2022.108959_bib108","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.sleep.2016.01.016","article-title":"Rotigotine may improve sleep architecture in Parkinson's disease: a double-blind, randomized, placebo-controlled polysomnographic study","volume":"21","author":"Pierantozzi","year":"2016","journal-title":"Sleep Med."},{"issue":"11","key":"10.1016\/j.neuropharm.2022.108959_bib109","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1002\/mds.23135","article-title":"Parkinson's disease symptoms: the patient's perspective","volume":"25","author":"Politis","year":"2010","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"issue":"7","key":"10.1016\/j.neuropharm.2022.108959_bib110","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1212\/WNL.0b013e318263570d","article-title":"Caffeine for treatment of Parkinson disease: a randomized controlled trial","volume":"79","author":"Postuma","year":"2012","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.neuropharm.2022.108959_bib111","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0175797","article-title":"Altered detrusor contractility in MPTP-treated common marmosets with bladder hyperreflexia","volume":"12","author":"Pritchard","year":"2017","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.neuropharm.2022.108959_bib112","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1161\/HYPERTENSIONAHA.114.04225","article-title":"Efficacy of atomoxetine versus midodrine for the treatment of orthostatic hypotension in autonomic failure","volume":"64","author":"Ramirez","year":"2014","journal-title":"Hypertension"},{"issue":"7","key":"10.1016\/j.neuropharm.2022.108959_bib113","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1002\/jcph.678","article-title":"A randomized controlled exploratory pilot study to evaluate the effect of rotigotine transdermal patch on Parkinson's disease-associated chronic pain","volume":"56","author":"Rascol","year":"2016","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.108959_bib114","doi-asserted-by":"crossref","first-page":"16023","DOI":"10.1038\/npjparkd.2016.23","article-title":"Non-oral dopaminergic therapies for Parkinson's disease: current treatments and the future","volume":"2","author":"Ray Chaudhuri","year":"2016","journal-title":"NPJ Parkinson's disease"},{"key":"10.1016\/j.neuropharm.2022.108959_bib115","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.parkreldis.2016.03.002","article-title":"Pharmacological interventions for daytime sleepiness and sleep disorders in Parkinson's disease: systematic review and meta-analysis","volume":"27","author":"Rodrigues","year":"2016","journal-title":"Park. Relat. Disord."},{"issue":"4","key":"10.1016\/j.neuropharm.2022.108959_bib116","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/WCO.0000000000000711","article-title":"Pain in Parkinson's disease: new concepts in pathogenesis and treatment","volume":"32","author":"Rukavina","year":"2019","journal-title":"Curr. Opin. Neurol."},{"issue":"3","key":"10.1016\/j.neuropharm.2022.108959_bib117","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/14737175.2021.1883428","article-title":"Non-motor complications in late stage Parkinson's disease: recognition, management and unmet needs","volume":"21","author":"Rukavina","year":"2021","journal-title":"Expert Rev. Neurother."},{"issue":"2","key":"10.1016\/j.neuropharm.2022.108959_bib118","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/SPC.0000000000000546","article-title":"Pain in Parkinson's disease: mechanism-based treatment strategies","volume":"15","author":"Rukavina","year":"2021","journal-title":"Curr. Opin. Support. Palliat. Care"},{"issue":"5","key":"10.1016\/j.neuropharm.2022.108959_bib119","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/nau.22764","article-title":"A guideline for the management of bladder dysfunction in Parkinson's disease and other gait disorders","volume":"35","author":"Sakakibara","year":"2016","journal-title":"Neurourol. Urodyn."},{"issue":"6","key":"10.1016\/j.neuropharm.2022.108959_bib120","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.eurpsy.2008.04.002","article-title":"Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system","volume":"23","author":"San","year":"2008","journal-title":"Eur. Psychiatr."},{"issue":"5","key":"10.1016\/j.neuropharm.2022.108959_bib121","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1378\/chest.14-0970","article-title":"International classification of sleep disorders-third edition","volume":"146","author":"Sateia","year":"2014","journal-title":"Chest"},{"issue":"11","key":"10.1016\/j.neuropharm.2022.108959_bib122","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/mds.21428","article-title":"Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson's disease","volume":"22","author":"Schoffer","year":"2007","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"issue":"4","key":"10.1016\/j.neuropharm.2022.108959_bib123","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/ene.13260","article-title":"Pyridostigmine bromide versus fludrocortisone in the treatment of orthostatic hypotension in Parkinson's disease - a randomized controlled trial","volume":"24","author":"Schreglmann","year":"2017","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.neuropharm.2022.108959_bib124","first-page":"S42","article-title":"The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson's disease","volume":"3","author":"Seppi","year":"2011","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"issue":"S3","key":"10.1016\/j.neuropharm.2022.108959_bib125","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1002\/mds.23884","article-title":"The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson's disease","volume":"26","author":"Seppi","year":"2011","journal-title":"Mov. Disord."},{"issue":"2","key":"10.1016\/j.neuropharm.2022.108959_bib126","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/mds.27602","article-title":"Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review","volume":"34","author":"Seppi","year":"2019","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"issue":"2","key":"10.1016\/j.neuropharm.2022.108959_bib127","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/mds.27602","article-title":"Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review","volume":"34","author":"Seppi","year":"2019","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"issue":"2","key":"10.1016\/j.neuropharm.2022.108959_bib128","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/mds.27602","article-title":"Update on treatments for nonmotor symptoms of Parkinson's disease\u2014an evidence-based medicine review","volume":"34","author":"Seppi","year":"2019","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.neuropharm.2022.108959_bib129","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1161\/HYPERTENSIONAHA.107.089961","article-title":"Norepinephrine transporter blockade with atomoxetine induces hypertension in patients with impaired autonomic function","volume":"50","author":"Shibao","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.neuropharm.2022.108959_bib130","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jns.2019.04.029","article-title":"Clonazepam for probable REM sleep behavior disorder in Parkinson's disease: a randomized placebo-controlled trial","volume":"401","author":"Shin","year":"2019","journal-title":"J. Neurol. Sci."},{"issue":"3","key":"10.1016\/j.neuropharm.2022.108959_bib131","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/WNF.0b013e318193e394","article-title":"Successful treatment of REM sleep behavior disorder with sodium oxybate","volume":"32","author":"Shneerson","year":"2009","journal-title":"Clin. Neuropharmacol."},{"issue":"3","key":"10.1016\/j.neuropharm.2022.108959_bib132","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/ejp.942","article-title":"Effect of medical cannabis on thermal quantitative measurements of pain in patients with Parkinson's disease","volume":"21","author":"Shohet","year":"2017","journal-title":"Eur. J. Pain"},{"issue":"4","key":"10.1016\/j.neuropharm.2022.108959_bib133","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s10286-016-0363-9","article-title":"Clinical benefit of midodrine hydrochloride in symptomatic orthostatic hypotension: a phase 4, double-blind, placebo-controlled, randomized, tilt-table study","volume":"26","author":"Smith","year":"2016","journal-title":"Clin. Auton. Res. Off. J. Clin. Aut. Res. Soc."},{"issue":"5","key":"10.1016\/j.neuropharm.2022.108959_bib134","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/mds.27018","article-title":"REM sleep behavior disorder in Parkinson's disease and other synucleinopathies","volume":"32","author":"St Louis","year":"2017","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2022.108959_bib135","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.sleep.2021.02.038","article-title":"Nelotanserin as symptomatic treatment for rapid eye movement sleep behavior disorder: a double-blind randomized study using video analysis in patients with dementia with Lewy bodies or Parkinson's disease dementia","volume":"81","author":"Stefani","year":"2021","journal-title":"Sleep Med."},{"key":"10.1016\/j.neuropharm.2022.108959_bib136","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1007\/PL00007731","article-title":"Sleep disorders in Parkinson's disease","volume":"1","author":"Stocchi","year":"1998","journal-title":"J. Neurol."},{"key":"10.1016\/j.neuropharm.2022.108959_bib137","unstructured":"Theranexus announces the success of its phase 2 trial for THN 102 in Parkinson's patients. [Available from:: https:\/\/www.actusnews.com\/en\/THERANEXUS\/pr\/2020\/03\/31\/theranexus-announces-the-success-of-its-phase-ii-trial-for-thn102-in-parkinson_s-patients."},{"issue":"5","key":"10.1016\/j.neuropharm.2022.108959_bib138","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/practneurol-2013-000741","article-title":"Ray Chaudhuri K. Non-motor Parkinson's: integral to motor Parkinson's, yet often neglected","volume":"14","author":"Todorova","year":"2014","journal-title":"Practical Neurol."},{"issue":"1","key":"10.1016\/j.neuropharm.2022.108959_bib139","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/mds.23441","article-title":"Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER)","volume":"26","author":"Trenkwalder","year":"2011","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"issue":"4","key":"10.1016\/j.neuropharm.2022.108959_bib140","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/mds.23476","article-title":"Parkinson's disease sleep scale\u2013validation of the revised version PDSS-2","volume":"26","author":"Trenkwalder","year":"2011","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"issue":"12","key":"10.1016\/j.neuropharm.2022.108959_bib141","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/S1474-4422(15)00243-4","article-title":"Prolonged-release oxycodone-naloxone for treatment of severe pain in patients with Parkinson's disease (PANDA): a double-blind, randomised, placebo-controlled trial","volume":"14","author":"Trenkwalder","year":"2015","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.neuropharm.2022.108959_bib142","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1093\/ageing\/afx167","article-title":"Z-drugs and risk for falls and fractures in older adults-a systematic review and meta-analysis","volume":"47","author":"Treves","year":"2018","journal-title":"Age Ageing"},{"issue":"10","key":"10.1016\/j.neuropharm.2022.108959_bib143","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.parkreldis.2011.04.016","article-title":"Prevalence of orthostatic hypotension in Parkinson's disease: a systematic review and meta-analysis","volume":"17","author":"Velseboer","year":"2011","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.neuropharm.2022.108959_bib144","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.expneurol.2012.08.018","article-title":"Circadian and sleep disorders in Parkinson's disease","volume":"243","author":"Videnovic","year":"2013","journal-title":"Exp. Neurol."},{"issue":"7","key":"10.1016\/j.neuropharm.2022.108959_bib145","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1136\/jnnp-2020-322875","article-title":"Clinical trials in REM sleep behavioural disorder: challenges and opportunities","volume":"91","author":"Videnovic","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"8","key":"10.1016\/j.neuropharm.2022.108959_bib146","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1136\/gutjnl-2018-316029","article-title":"Guanylate cyclase-C as a therapeutic target in gastrointestinal disorders","volume":"67","author":"Waldman","year":"2018","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.neuropharm.2022.108959_bib147","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41467-019-14189-9","article-title":"Autonomic ganglionic injection of \u03b1-synuclein fibrils as a model of pure autonomic failure \u03b1-synucleinopathy","volume":"11","author":"Wang","year":"2020","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.neuropharm.2022.108959_bib148","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2165\/11631990-000000000-00000","article-title":"Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder","volume":"26","author":"Weisler","year":"2012","journal-title":"CNS Drugs"},{"issue":"4","key":"10.1016\/j.neuropharm.2022.108959_bib149","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/mds.28001","article-title":"Genome-wide association study of pain in Parkinson's disease implicates TRPM8 as a risk factor. Movement disorders","volume":"35","author":"Williams","year":"2020","journal-title":"Off. J. Mov. Disord. Soc."},{"issue":"1","key":"10.1016\/j.neuropharm.2022.108959_bib150","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3233\/JPD-202260","article-title":"Cannabis in Parkinson's disease: the patients' view","volume":"11","author":"Yenilmez","year":"2021","journal-title":"J. Parkinsons Dis."},{"issue":"11","key":"10.1016\/j.neuropharm.2022.108959_bib151","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1007\/s10072-015-2288-9","article-title":"Parkinson's disease and insomnia","volume":"36","author":"Ylikoski","year":"2015","journal-title":"Neurol. Sci."},{"issue":"6","key":"10.1016\/j.neuropharm.2022.108959_bib152","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1007\/s10072-019-03785-8","article-title":"Excessive daytime sleepiness and its impact on quality of life in de novo Parkinson's disease","volume":"40","author":"Yoo","year":"2019","journal-title":"Neurol. Sci."},{"issue":"9","key":"10.1016\/j.neuropharm.2022.108959_bib153","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/mds.21243","article-title":"Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo-controlled study","volume":"22","author":"Zangaglia","year":"2007","journal-title":"Mov. Disord. : Off. J. Mov. Disord. Soc."},{"issue":"5","key":"10.1016\/j.neuropharm.2022.108959_bib154","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.parkreldis.2015.02.025","article-title":"Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson's disease","volume":"21","author":"Zesiewicz","year":"2015","journal-title":"Park. Relat. Disord."},{"issue":"4","key":"10.1016\/j.neuropharm.2022.108959_bib155","doi-asserted-by":"crossref","first-page":"711","DOI":"10.33549\/physiolres.934478","article-title":"Inhibition of NADPH oxidase within midbrain periaqueductal gray decreases pain sensitivity in Parkinson's disease via GABAergic signaling pathway","volume":"69","author":"Zhang","year":"2020","journal-title":"Physiol. Res."},{"key":"10.1016\/j.neuropharm.2022.108959_bib156","first-page":"8834950","article-title":"Efficacy and safety of pramipexole sustained release versus immediate release formulation for nocturnal symptoms in Chinese patients with advanced Parkinson's disease: a pilot study","volume":"2021","author":"Zhou","year":"2021","journal-title":"Parkinsons Dis"},{"issue":"4","key":"10.1016\/j.neuropharm.2022.108959_bib157","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1007\/s13311-020-00938-y","article-title":"Sleep issues in Parkinson's disease and their management","volume":"17","author":"Zuzu\u00e1rregui","year":"2020","journal-title":"Neurotherapeutics"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390822000181?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390822000181?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:17:04Z","timestamp":1758439024000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390822000181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":158,"alternative-id":["S0028390822000181"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2022.108959","relation":{},"ISSN":["0028-3908"],"issn-type":[{"type":"print","value":"0028-3908"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New approaches to treatments for sleep, pain and autonomic failure in Parkinson's disease - Pharmacological therapies","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2022.108959","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108959"}}